Meklonatsepaami

Meclonazepam is a benzodiazepine derivative structurally related to clonazepam, first developed by Hoffmann-La Roche during the 1960s. It was initially investigated for potential antiparasitic applications, particularly in the treatment of schistosomiasis. Although it has appeared on the grey market as a recreational depressant, it has not achieved widespread use. As with other benzodiazepines, meclonazepam is considered habit-forming and carries the risk of physical dependence with repeated administration.

Also known as: Methylclonazepam, 3-Methylclonazepam

Classification

Chemical: Benzodiazepine
Chemical: Medicine
Psychoactive: Depressant
Tag: 1,4-Benzodiazepine
Tag: Anticonvulsant
Tag: Anxiolytic
Tag: GABAergic
Tag: Habit-Forming
Tag: Muscle Relaxant
Tag: Sedative
Tag: Tentative

Effects

Sedation
Muscle Relaxation
Anxiolytic
Sedative
Dystaxia
Hypnotic
Anxiety Suppression
Amnesia
Motor Control Loss
Reduced Anxiety
Euphoria
Thought Deceleration
Dulled Perception
Disinhibition
Open Eye Visuals
Double Vision
Blurred Vision
Voices

Routes of Administration

Oral

Dosage

Heavy: 6-12 mg
Common: 3 – 6 mg

Duration

Onset: 0.33-1 h
After Effects: 1-6 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu